Taking on Children’s Cancer from Every Direction
We’re disrupting the status quo with our bold vision for young patients – to not only survive their cancer but thrive in their lives after treatment.
While many children survive acute lymphoblastic leukemia, the most common type of pediatric blood cancer, the treatments are harsh and outdated. The long-term effects of current therapies can create severe life-threatening complications. And survival rates for children with other high-risk types of leukemia, such as acute myeloid leukemia, are very poor. That’s why we are more than doubling our investment in pediatric research.
What’s more, LLS is pioneering an unprecedented collaborative clinical trial to fundamentally change the way pediatric blood cancers are treated, while expanding the services and support we provide for children and families.